The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond the loss of life and suffering is real in many stocks, sectors…
The Wuhan Coronavirus has already left China and hit neighboring countries, the U.S. and even in Europe in Australia. As the death toll and number of infected are rising each hour, the…
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.
Chris Lange Every week we search for stocks covered by top Wall Street analysts that are trading under the $10 level and could provide solid upside potential. This week we found five companies covered…
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
BioCryst Pharmaceuticals shares fell on Tuesday after the company announced initial results from its hereditary angioedema trial.
Chris Lange The top analyst upgrades, downgrades and other research calls from Tuesday include Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft and Netflix.
Idera Pharmaceuticals shares crumbled on Wednesday after BioCryst Pharmaceuticals announced that it terminated the merger agreement.
Chris Lange The top analyst upgrades, downgrades and other research calls from Friday include Bookings Holdings, Dollar General, KLA-Tencor, Micron Technology, Nike and Red Hat.
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
Chris Lange BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
Chris Lange The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Thursday include BioCryst Pharmaceuticals, Cisco Systems, Groupon, SunPower, Tesla and Wells Fargo.
